World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 98 8802 8261 101 97 830 44826

Marc Peeters publications per year

The chart shows the history of publications by Marc Peeters between 1991 and 2026, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Marc Peeters published across 36 years, from 1991 to 2026, averaging 30.9 papers a year. Output peaked at 181 publications in 2023. 38 of the 1,111 publications appeared in the last two years.

No. of publications
50 100 150
Bar chart. Horizontal axis: year, 1991 to 2026. Vertical axis: number of publications, 0 to 181. Peak 181 publications in 2023. 1991: 1 publication 1992: 2 publications 1993: 0 publications 1994: 1 publication 1995: 9 publications 1996: 12 publications 1997: 16 publications 1998: 16 publications 1999: 13 publications 2000: 19 publications 2001: 11 publications 2002: 4 publications 2003: 13 publications 2004: 15 publications 2005: 15 publications 2006: 25 publications 2007: 33 publications 2008: 45 publications 2009: 37 publications 2010: 39 publications 2011: 45 publications 2012: 47 publications 2013: 32 publications 2014: 43 publications 2015: 51 publications 2016: 53 publications 2017: 51 publications 2018: 52 publications 2019: 35 publications 2020: 29 publications 2021: 45 publications 2022: 36 publications 2023: 181 publications 2024: 47 publications 2025: 36 publications 2026: 2 publications
1991 2026

1,111 publications in total across all disciplines

View publications per year as a table
Marc Peeters: publications per year, 1991 to 2026
Year Publications
1991 1
1992 2
1993 0
1994 1
1995 9
1996 12
1997 16
1998 16
1999 13
2000 19
2001 11
2002 4
2003 13
2004 15
2005 15
2006 25
2007 33
2008 45
2009 37
2010 39
2011 45
2012 47
2013 32
2014 43
2015 51
2016 53
2017 51
2018 52
2019 35
2020 29
2021 45
2022 36
2023 181
2024 47
2025 36
2026 2
Total 1,111
Download as CSV

Marc Peeters publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Marc Peeters sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 821–840 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 830 publications — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186 830
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Marc Peeters D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Marc Peeters sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 98–99 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 98 D-Index — 57th percentile

57% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668 98
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Marc Peeters is affiliated with the University of Antwerp in Belgium and has an extensive publication record specializing in oncology and related medical fields. Their research contributions are primarily focused on cancer treatments, immunotherapy, genomics, and diagnostics, among other medical subfields. Peeters has contributed to over 400 publications in medicine, with a significant emphasis on oncology.

Their recent published papers include:

  • Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study (2023, The Lancet Oncology)
  • Epidemiology of spinal metastases, metastatic epidural spinal cord compression and pathologic vertebral compression fractures in patients with solid tumors: A systematic review (2022, Journal of Bone Oncology)
  • Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial (2020, Annals of Oncology)
  • Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment (2021, ESMO Open)
  • Auranofin reveals therapeutic anticancer potential by triggering distinct molecular cell death mechanisms and innate immunity in mutant p53 non-small cell lung cancer (2021, Redox Biology)

Marc Peeters has collaborated extensively with other researchers. Frequent co-authors include:

  • Peter A. van Dam
  • Timon Vandamme
  • Hans Prenen
  • Evelien Smits
  • Filip Lardon

Their scholarly work has been published in various prominent journals, with multiple contributions to:

  • Annals of Oncology
  • Cancers
  • ESMO Open
  • European Journal of Cancer
  • Journal of Clinical Oncology

Marc Peeters has written on several main topics within their field including:

  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • COVID-19 and Healthcare Impacts
  • Pancreatic and Hepatic Oncology Research
  • Lung Cancer Treatments and Mutations

Their publications span subfields such as:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Cancer Research
  • Surgery

Marc Peeters is also an author of a textbook published by Springer International Publishing titled Practical Medical Oncology Textbook (2021), which has been cited in academic literature.

Best Publications

  • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

    Rafael G. Amado;Michael Wolf;Marc Peeters;Eric Van Cutsem

  • Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

    Eric Van Cutsem;Marc Peeters;Salvatore Siena;Yves Humblet

  • Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer

    Robert J Mayer;Eric Van Cutsem;Alfredo Falcone;Takayuki Yoshino

  • Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

    Marianne E Pavel;John D Hainsworth;Eric Baudin;Marc Peeters

  • Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

    Marc Peeters;Timothy Jay Price;Andrés Cervantes;Alberto F. Sobrero

  • KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

    W. De Roock;H. Piessevaux;J. De Schutter;M. Janssens

  • Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum

    P Rutgeerts;M Peeters;M Hiele;G Vantrappen

  • Controlled trial of metronidazole treatment for prevention of crohn's recurrence after ileal resection☆

    Paul Rutgeerts;Martin Hiele;Karel Geboes;Marc Peeters

  • Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.

    D. Arnold;B. Lueza;J.-Y. Douillard;M. Peeters

  • Utility of Positron Emission Tomography for the Staging of Patients With Potentially Operable Esophageal Carcinoma

    P Flamen;A Lerut;E Van Cutsem;W De Wever

  • Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis

    Filip J. Baert;Geert R. D'Haens;Marc Peeters;Martin I. Hiele

  • Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study

    E. Van Cutsem;F. Rivera;S. Berry;A. Kretzschmar

  • Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study.

    Timothy J Price;Marc Peeters;Tae Won Kim;Jin Li

  • Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis.

    G D'Haens;L Lemmens;Karel Geboes;L Vandeputte

  • Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.

    Alain Hendlisz;Marc Van Den Eynde;Marc Peeters;Geert Maleux

  • Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease

    Marc Peeters;Sofie Joossens;Severine Vermeire;Robert Vlietinck

  • Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab

    Bart Jacobs;Wendy De Roock;Hubert Piessevaux;Robin Van Oirbeek

  • Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics

    M Peeters;H Nevens;F Baert;M Hiele

  • The value of serologic markers in indeterminate colitis : a prospective follow-up study

    Sofie Joossens;Walter Reinisch;Séverine Vermeire;Boualem Sendid

  • A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.

    Helmut Oettle;D. Richards;R. K. Ramanathan;J. L. van Laethem

Frequent Co-Authors

Patrick Pauwels
Patrick Pauwels University of Antwerp
Jan B. Vermorken
Jan B. Vermorken University of Antwerp
Salvatore Siena
Salvatore Siena University of Milan
Evelien Smits
Evelien Smits University of Antwerp
Guy Van Camp
Guy Van Camp University of Antwerp
Antonio Russo
Antonio Russo University of Palermo
Volker Heinemann
Volker Heinemann Ludwig-Maximilians-Universität München

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're considering a career in medicine but aren’t ready for the commitment of a traditional MD program, there are several related pathways to explore. Many students begin by looking into nursing schools, and you might wonder what is the easiest nursing school to get into to jumpstart your healthcare journey.

For those interested in a non-clinical role, medical billing and coding schools online offer flexible programs that can prepare you for administrative and IT-focused positions in the healthcare industry.

There are also fast-track options for current nurses, such as lpn to rn programs without teas test, which eliminate common admission exams and help you advance your credentials quickly.

If you’re drawn to leadership and organizational roles, a healthcare administration online degree can open doors to managerial positions in hospitals, clinics, and more—all from the convenience of your home.

Best Scientists Citing Marc Peeters

Trending Scientists

Recently Published Articles